Item Type | Name |
Concept
|
Hematopoietic Stem Cells
|
Concept
|
Stem Cells
|
Concept
|
Hematopoietic Stem Cell Transplantation
|
Concept
|
Stem Cell Transplantation
|
Concept
|
Hematopoietic Stem Cell Mobilization
|
Concept
|
Peripheral Blood Stem Cell Transplantation
|
Concept
|
Cord Blood Stem Cell Transplantation
|
Concept
|
Neoplastic Stem Cells
|
Academic Article
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse following Allogeneic Stem Cell Transplantation. Part I: Methods, acute leukemias, and myelodysplastic syndromes.
|
Academic Article
|
NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on disease-specific methods and strategies for monitoring relapse following allogeneic stem cell transplantation. part II: chronic leukemias, myeloproliferative neoplasms, and lymphoid malignancies.
|
Academic Article
|
Disseminated aspergillosis caused by Aspergillus ustus in a patient following allogeneic peripheral stem cell transplantation.
|
Academic Article
|
Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation.
|
Academic Article
|
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for metastatic breast cancer.
|
Academic Article
|
Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion.
|
Academic Article
|
Establishing a platform for immunotherapy: clinical outcome and study of immune reconstitution after high-dose chemotherapy with progenitor cell support in breast cancer patients.
|
Academic Article
|
Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor.
|
Academic Article
|
Immunoablative reduced-intensity stem cell transplantation: potential role of donor Th2 and Tc2 cells.
|
Academic Article
|
Nonmyeloablative allogeneic stem cell transplantation: early promise and limitations.
|
Academic Article
|
Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies.
|
Academic Article
|
Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia.
|
Academic Article
|
Immunotherapy of metastatic breast cancer: phase I trail of reduced-intensity allogeneic hematopoietic stem cell transplantation with Th2/Tc2 T-cell exchange.
|
Academic Article
|
Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer.
|
Academic Article
|
Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies.
|
Academic Article
|
Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Host T cells affect donor T cell engraftment and graft-versus-host disease after reduced-intensity hematopoietic stem cell transplantation.
|
Academic Article
|
Principles and overview of allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Relapse after allogeneic hematopoietic cell therapy.
|
Academic Article
|
A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation.
|
Academic Article
|
Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes.
|
Academic Article
|
Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
|
Academic Article
|
National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.
|
Academic Article
|
Strategies to improve long-term outcome in stage IIIB inflammatory breast cancer: multimodality treatment including dose-intensive induction and high-dose chemotherapy.
|
Academic Article
|
Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population.
|
Academic Article
|
A multicenter pilot evaluation of the National Institutes of Health chronic graft-versus-host disease (cGVHD) therapeutic response measures: feasibility, interrater reliability, and minimum detectable change.
|
Academic Article
|
Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
|
Academic Article
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.
|
Academic Article
|
Allogeneic hematopoietic stem cell transplantation for lymphoma.
|
Academic Article
|
Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation.
|
Academic Article
|
Allogeneic hematopoietic stem cell transplantation for metastatic breast cancer.
|
Academic Article
|
Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
|
Academic Article
|
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science.
|
Academic Article
|
Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis.
|
Academic Article
|
Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas.
|
Academic Article
|
Allogeneic hematopoietic stem cell transplantation: does it have a place in treating Hodgkin lymphoma?
|
Academic Article
|
Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation.
|
Academic Article
|
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation.
|
Academic Article
|
Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Function, adjustment, quality of life and symptoms (FAQS) in allogeneic hematopoietic stem cell transplantation (HSCT) survivors: a study protocol.
|
Academic Article
|
Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies.
|
Academic Article
|
Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-hodgkin lymphoma.
|
Academic Article
|
Donor lymphocyte infusion: beauty is in the eye of the beholder.
|
Academic Article
|
Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in myeloma patients.
|
Academic Article
|
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Health-related quality of life in patients receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels.
|
Academic Article
|
A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display.
|
Academic Article
|
Correlation of pretransplant and early post-transplant response assessment with outcomes after reduced-intensity allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
|
Academic Article
|
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.
|
Academic Article
|
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
|
Academic Article
|
Minimal residual disease following allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma: a concise review.
|
Academic Article
|
Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.
|
Academic Article
|
Dose-adjusted EPOCH-rituximab combined with fludarabine provides an effective bridge to reduced-intensity allogeneic hematopoietic stem-cell transplantation in patients with lymphoid malignancies.
|
Academic Article
|
Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies.
|
Academic Article
|
Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.
|
Academic Article
|
Filgrastim as an alternative to donor leukocyte infusion for relapse after allogeneic stem-cell transplantation.
|
Academic Article
|
Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Bioethical considerations of monoclonal B-cell lymphocytosis: donor transfer after haematopoietic stem cell transplantation.
|
Academic Article
|
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.
|
Academic Article
|
Gastroparesis as a cause of nausea and vomiting after high-dose chemotherapy and haemopoietic stem-cell transplantation.
|
Academic Article
|
Association of serum interleukin-7 levels with the development of acute graft-versus-host disease.
|
Academic Article
|
EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT.
|
Academic Article
|
Pseudoautologous blood stem cell transplantation for refractory chronic graft-versus-host disease.
|
Academic Article
|
Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience.
|
Academic Article
|
High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma.
|
Academic Article
|
Factors affecting engraftment of allogeneic hematopoietic stem cells after reduced-intensity conditioning.
|
Academic Article
|
Hematopoietic stem cell transplantation. Introduction.
|
Academic Article
|
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.
|
Academic Article
|
Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia.
|
Academic Article
|
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.
|
Academic Article
|
Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis.
|
Academic Article
|
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Treatments of disease relapse after allogeneic stem cell transplantation focusing on donor lymphocyte infusion.
|
Academic Article
|
Host lymphocyte depletion as a strategy to facilitate early full donor chimerism after reduced-intensity allogeneic stem cell transplantation.
|
Academic Article
|
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction.
|
Academic Article
|
Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of relapse after transplantation.
|
Academic Article
|
Emergencies related to cancer chemotherapy and hematopoietic stem cell transplantation.
|
Academic Article
|
Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
|
Academic Article
|
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.
|
Academic Article
|
Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors.
|
Academic Article
|
Potential use of hematopoietic stem cells after radiation injury.
|
Academic Article
|
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
|
Academic Article
|
Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients.
|
Academic Article
|
Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer.
|
Academic Article
|
Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease.
|
Academic Article
|
Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease.
|
Academic Article
|
The role of high-dose therapy with hematopoietic stem cell rescue in low-grade non-Hodgkin's lymphoma.
|
Academic Article
|
Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research.
|
Academic Article
|
Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients.
|
Academic Article
|
Development of severe sclerotic chronic GVHD during treatment with dasatinib.
|
Academic Article
|
High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy.
|
Academic Article
|
Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission.
|
Academic Article
|
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.
|
Academic Article
|
Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival.
|
Academic Article
|
High-Dose Sirolimus and Immune-Selective Pentostatin plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-versus-Tumor Responses.
|
Academic Article
|
Antitumor activity of human umbilical cord blood cells: A comparative analysis with peripheral blood and bone marrow cells.
|
Academic Article
|
Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.
|
Academic Article
|
Oligonucleotide enhanced cytotoxicity of Idarubicin for lymphoma cells.
|
Academic Article
|
Incidence and predictors of respiratory viral infections by multiplex PCR in allogeneic hematopoietic cell transplant recipients 50 years and older including geriatric assessment.
|
Academic Article
|
PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
|
Academic Article
|
Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents.
|
Academic Article
|
High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma.
|
Academic Article
|
The risk of secondary leukemias following autologous stem cell transplantation.
|
Academic Article
|
Blood stem cell transplantation in non-Hodgkin's lymphoma.
|
Academic Article
|
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.
|
Academic Article
|
Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.
|
Academic Article
|
Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia.
|
Academic Article
|
Characterization of cancer comorbidity prior to allogeneic hematopoietic cell transplantation.
|
Academic Article
|
Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis.
|
Academic Article
|
Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning.
|
Academic Article
|
Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults.
|
Academic Article
|
Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.
|
Academic Article
|
Dose escalation prophylactic donor lymphocyte infusion after T-cell depleted matched related donor allogeneic hematopoietic cell transplantation is feasible and results in higher donor chimerism, faster immune re-constitution, and prolonged progression-free survival.
|
Academic Article
|
Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy following Allogeneic Stem Cell Transplantation.
|
Academic Article
|
Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients.
|
Academic Article
|
Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies.
|